Jerusalem. Israeli researchers and their colleagues from the United States have developed an antibody-based treatment that enables the body’s immune system to effectively attack cancer cells and stop their spread. Israel’s Weizmann Institute of Science (WIS) said in a statement on Monday. WIS-led scientists revealed that a form of breast cancer known as triple-negative breast cancer encourages nearby immune cells to form molecular bridges.
These bridges prevent immune cells from attacking the tumor, resulting in decreased immunity. The research team demonstrated this through a mouse model. Told that antibody treatment that prevents the formation of these bridges proves to be effective. These can revive the immune system to work efficiently against the bacteria that attack cancer cells. The researchers explained that while breast cancer cells themselves produce small amounts of the protein CD84 (which is an immunoreceptor), the protein used to form bridges also produces large amounts of this protein to nearby immune cells. Induce production, thereby suppressing immunity.
The study also found that higher levels of CD84 in patients’ tumors were associated with lower survival rates. Experiments in CD84-deficient mice (experimental) showed that tumors were smaller in size, highlighting how CD84 suppresses immune system T cell activity in the tumor environment. When mice (experimental) suffering from breast cancer were treated with antibodies twice a week, it was found that this significantly slowed down the growth of tumors and in some cases even helped in their complete recovery. The team noted that the antibody selectively targets cells with high CD84 levels and spares healthy immune cells. And in this way this antibody stops this harmful protein from emerging. According to researchers, this treatment may help treat different cancer types, including the tumor microenvironment rather than the cancer cells themselves.